Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E –mutated colorectal cancer
Approximately, 10% of metastatic colorectal cancers display BRAF V600E mutation. Although originally associated with poor outcomes, new targeted therapies have improved their prognosis. The phase III multicenter randomised BEACON trial showed that, second-line triple therapy combining binimetinib, encorafenib and cetuximab improved response rate, as well as progression-free and overall survival among these patients [1]. No nephrotoxicity has yet been reported with the association of these three drugs.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Romain Stammler, Claire Gallois, Julien Taieb, Jean-Paul Duong, Alexandre Karras, Eric Thervet, H élène Lazareth Tags: Letter to the Editor Source Type: research